UCB's Phase III lupus failure casts further shadow over field
This article was originally published in Scrip
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.
You may also be interested in...
Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.